Research programme: metabolic disorders therapy - Metabolex/Takeda

Drug Profile

Research programme: metabolic disorders therapy - Metabolex/Takeda

Latest Information Update: 20 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metabolex; Takeda
  • Developer CymaBay Therapeutics; Takeda
  • Class Antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 10 Dec 2013 Discontinued for Metabolic disorders in USA (unspecified route)
  • 15 Apr 2010 Early research in Metabolic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top